Evidence map›Paper›PMID 42435407›Full record

ArticleBioinformatics (Oxford, England)2026

CellPyAbility: automated image analysis for high-throughput dose-response screening.

James L Elia, Sam Friedman, Ranjit S Bindra

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

James L EliaDepartment of Pathology, Yale School of Medicine, New Haven, CT 06510, United States.ORCID 0000-0003-3962-7452
Sam FriedmanYale Center for Research Computing, Yale University, New Haven, CT 06511, United States.
Ranjit S BindraDepartment of Pathology, Yale School of Medicine, New Haven, CT 06510, United States.ORCID 0000-0002-3255-0467

Funding

Therapy Evaluation CoreU19CA264362 · NCI · MAYO CLINIC ROCHESTER · PI PARNEY, IAN F · 2021 to 2025
$7.6M
Yale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6M
Novel therapeutics for the targeted eradication of DDR-defective tumorsR01CA276186 · NCI · YALE UNIVERSITY · PI Ranjit Bindra, Seth B. Herzon · 2023 to 2026
$2.6M
Exploiting Homologous Recombination Defects with a Novel DNA-Crosslinking StrategyF31CA294600 · NCI · YALE UNIVERSITY · PI ELIA, JAMES LAURENCE · 2025 to 2025
$50k
NCI NIH HHS F31 CA294600NCI NIH HHS R01 CA276186NCI NIH HHS T32 CA193200NCI NIH HHS U19 CA264362NIH HHS F31CA294600NIH HHS R01CA276186NIH HHS T32CA193200NIH HHS U19CA264362
6 · The paper itself

Abstract

summaryNuclei counting provides a low-cost, metabolic-independent alternative to ATP- or tetrazolium-based cell viability assays. However, the fragmentation of image processing, normalization, and statistical modeling across multiple software platforms hinders high-throughput adoption. We present CellPyAbility, a Python-based suite that automates image processing, dose-response fitting, and synergy analysis. It converts unedited whole-well images into publication-ready graphics in under 1 minute per 96-well plate on standard desktop hardware. AVAILABILITY AND IMPLEMENTATION: CellPyAbility is open-source (MIT License) and available as a Python package via PyPI and Bioconda, or as a code-free application for macOS and Windows. Source code and documentation are available at https://github.com/bindralab/cellpyability and on Zenodo at https://doi.org/10.5281/zenodo.20693745.

Indexed as

High-Throughput Screening AssaysImage Processing, Computer-AssistedSoftware

Identifiers

PMID42435407
PMCPMC13401477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.